A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...

書誌詳細
主要な著者:	Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
フォーマット:	論文
言語:	English
出版事項:	SAGE Publishing 2022-09-01
シリーズ:	Cancer Control
オンライン･アクセス:	https://doi.org/10.1177/10732748221130576

類似資料

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
著者:: Hiroki Hata MS, 等
出版事項: (2020-12-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
著者:: Hideo Oishi, MD, 等
出版事項: (2020-10-01)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
著者:: Arthur E. Frankel MD, 等
出版事項: (2019-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
著者:: Taichi Miyawaki, MD, 等
出版事項: (2020-06-01)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
著者:: Bilguun Erkhem-Ochir, MD, 等
出版事項: (2021-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
著者:: Samit Chatterjee PhD, 等
出版事項: (2017-07-01)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
著者:: Tara Davidson, MD, 等
出版事項: (2022-07-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
著者:: Chenxing Zhang, PhD, 等
出版事項: (2020-03-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
著者:: Daisuke Hazama, MD, PhD, 等
出版事項: (2024-01-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
著者:: Tatsuya Nishikawa, MD, PhD, 等
出版事項: (2022-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
著者:: Kenji Morimoto, MD, PhD, 等
出版事項: (2022-09-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
著者:: Mariana Mirabel, MD, PhD, 等
出版事項: (2020-09-01)

A Modified Method for the Quantification of Immune Checkpoint Ligands on Exosomes from Human Serum using Flow Cytometry
著者:: Alan Guillermo Alejandre Gonzalez PhD, 等
出版事項: (2023-05-01)

A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8
著者:: Amanda Leiter, MD, MSCR, 等
出版事項: (2020-07-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
著者:: Yasunori Murata, MD, PhD, 等
出版事項: (2023-12-01)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
著者:: Fatih Kus MD, 等
出版事項: (2024-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
著者:: Shiting Xu, MD, 等
出版事項: (2022-04-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
著者:: Yuto Terashima, MD, 等
出版事項: (2023-11-01)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
著者:: Xinlun Dai MD, 等
出版事項: (2020-08-01)

Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
著者:: Lianghui Zhang MS, 等
出版事項: (2024-08-01)

A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
著者:: Mahdieh Azizi, PhD, 等
出版事項: (2024-01-01)

Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma
著者:: Qiang Liu PhD, 等
出版事項: (2024-04-01)

Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes
著者:: Etienne Charpentier, MD, 等
出版事項: (2024-01-01)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
著者:: Jack M. Qian, MD, 等
出版事項: (2022-03-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
著者:: Mandy Jongbloed, MD, 等
出版事項: (2025-03-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
著者:: Dorothy M. Gujral, PhD, 等
出版事項: (2020-02-01)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
著者:: Ying Teng PhD, 等
出版事項: (2022-03-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
著者:: Tristan V.M. Bruijn, MD, 等
出版事項: (2024-05-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
著者:: Kana Hashimoto, MD, 等
出版事項: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
著者:: Natalie Bourand, MS, 等
出版事項: (2025-02-01)

Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo
著者:: Hsin-Ling Yang PhD, 等
出版事項: (2017-09-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
著者:: Roger Y. Kim, MD, 等
出版事項: (2021-06-01)

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
著者:: Benjamin M.P. Elyan, MBChB, 等
出版事項: (2023-07-01)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
著者:: Marco Tagliamento, MD, 等
出版事項: (2023-01-01)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
著者:: Denis L. Jardim MD, PhD, 等
出版事項: (2018-12-01)

Seeking “protective” and “harmful” immune genes during chronic HIV-1 infection by transcriptome analysis
著者:: Lingyan Zhu, PhD, 等
出版事項: (2018-09-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
著者:: Alicia Quilez, MD, 等
出版事項: (2020-03-01)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation
著者:: Jia-Jun Wu, MD, 等
出版事項: (2022-06-01)

The Value of Combined Detection of Megakaryocyte and Platelet Parameters for the Diagnosis of Primary Immune Thrombocytopenia
著者:: Weiwei Wang MS, 等
出版事項: (2022-08-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
著者:: Sakeena Fatima, BA, 等
出版事項: (2018-04-01)